Business
D. Boral Capital Acted as Exclusive Placement Agent to Omeros Corporation (Nasdaq: OMER) in Connection with its $22,000,000 Registered Direct Offering
NEW YORK CITY, NEW YORK / ACCESS Newswire / July 31, 2025 / On July 24, 2025, Omeros Corporation (Nasdaq:OMER) ("Omeros" or the "Company") entered into a securities purchase agreement with Polar Asset Management Partners to sell approximately $22,000,000 ...
About this update from Omeros Corporation
[{"type":"text","content":"NEW YORK CITY, NEW YORK / ACCESS Newswire / July 31, 2025 / On July 24, 2025, Omeros Corporation (Nasdaq:OMER) ("Omeros" or the "Company") entered into a securities purchase agreement with Polar Asset Management Partners to sell approximately $22,000,000 of its common stock in a registered direct offering (the "Transaction"). The offering of the common stock was made pursuant to a "shelf" Registration Statement on Form S-3 (File No. 333-268269) and the accompanying prospectus. The Transaction closed on July 28, 2025, pursuant to which the Company sold 5,365,853 shares of its common stock at a price of $4.10 per share, which represents a premium of approximately 14% to the closing price of the Company's common stock on the date of the securities purchase agreement.","length":818,"tagName":"p"},{"type":"text","content":"D. Boral Capital LLC acted as exclusive placement agent for the Transaction.","length":76,"tagName":"p"},{"type":"text","content":"This press release does not constitute an offer to sell, or the solicitation of an offer to buy any of the Company's securities, nor shall there be any offer, solicitation or sale of any of the Company's securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.","length":407,"tagName":"p"},{"type":"text","content":"About Omeros Corporation","length":24,"tagName":"p"},{"type":"text","content":"Omeros is an innovative biopharmaceutical company committed to discovering, developing and commercializing first-in-class small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases and cancers, as well as addictive and compulsive disorders. Omeros' lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application under review by FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Omeros' long-acting MASP-2 inhibitor OMS1029 has successfully completed Phase 1 single- and multiple-ascending dose clinical studies. OMS906, Omeros' inhibitor of MASP-3, the key activator of the alternative pathway of comple...